HomeInsightsStock Comparison

Kopran Ltd vs Marksans Pharma Ltd Stock Comparison

Kopran Ltd vs Marksans Pharma Ltd Stock Comparison

Last Updated on: Jul 16, 2025

Key Highlights

  • The Latest Trading Price of Kopran Ltd is ₹ 181 as of 16 Jul 13:15.
  • The P/E Ratio of Kopran Ltd changed from 5.2 on March 2020 to 24.5 on March 2024 . This represents a CAGR of 36.34% over 5 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 4.7 on March 2020 to 21.9 on March 2024 . This represents a CAGR of 36.04% over 5 years.
  • The Market Cap of Kopran Ltd changed from ₹ 109.65 crore on March 2020 to ₹ 1245 crore on March 2024 . This represents a CAGR of 62.59% over 5 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 568.95 crore on March 2020 to ₹ 6867 crore on March 2024 . This represents a CAGR of 64.57% over 5 years.
  • The revenue of Kopran Ltd for the Mar '25 is ₹ 175.62 crore as compare to the Dec '24 revenue of ₹ 166.41 crore. This represent the growth of 5.53% The revenue of Marksans Pharma Ltd for the Mar '25 is ₹ 724.98 crore as compare to the Dec '24 revenue of ₹ 709.7 crore. This represent the growth of 2.15%.
  • The ebitda of Kopran Ltd for the Mar '25 is ₹ 20.35 crore as compare to the Dec '24 ebitda of ₹ 20.01 crore. This represent the growth of 1.7% The ebitda of Marksans Pharma Ltd for the Mar '25 is ₹ 142.27 crore as compare to the Dec '24 ebitda of ₹ 166.61 crore. This represent the decline of -14.61%.
  • The net profit of Kopran Ltd changed from ₹ 2.77 crore to ₹ 9.68 crore over 8 quarters. This represents a CAGR of 86.94% The net profit of Marksans Pharma Ltd changed from ₹ 70.44 crore to ₹ 90.73 crore over 8 quarters. This represents a CAGR of 13.49% .
  • The Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 41.75 % on March 2024 . This represents a CAGR of -6.78% over 4 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.8 % on March 2020 to 20.33 % on March 2024 . This represents a CAGR of 13.49% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Kopran Ltd

  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises.
  • The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment.
  • It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin.
  • Kopran also makes penicillin-G acylase, an enzyme made through fermentation.
  • It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

About Marksans Pharma Ltd

  • Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982.
  • Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005.
  • The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
  • The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
  • Marksans Pharma Limited (formerly M/s.

Kopran Ltd News Hub

News

Board of Kopran recommends final dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 15 May ...

Read more

15 May 2025 16:01

News

Kopran to hold board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025. Powere...

Read more

07 May 2025 14:37

News

Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly

The United States Food and Drug Administration (USFDA) recently carried out a surveillance...

Read more

28 Apr 2025 15:03

News

Kopran to declare Quarterly Results

Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025. P...

Read more

05 Feb 2025 12:53

News

Kopran allots 36,200 equity shares under ESOP

Kopran has allotted 36,200 equity shares under ESOP on 21 January 2025. With this allotmen...

Read more

21 Jan 2025 18:36

News

Kopran to discuss results

Kopran will hold a meeting of the Board of Directors of the Company on 13 November 2024 Po...

Read more

06 Nov 2024 14:37

Marksans Pharma Ltd News Hub

News

Marksans Pharma AGM scheduled

Marksans Pharma announced that the 33th Annual General Meeting(AGM) of the company will be...

Read more

11 Jul 2025 17:41

News

Time-Cap Laboratories successfully concludes USFDA inspection

Marksans Pharma announced that its subsidiary, Time-Cap Laboratories Inc. has received the...

Read more

30 Jun 2025 12:56

News

Marksans Pharma rises after subsidiary gets EIR for New York-based facility from US FDA

In April this year, the United States Food and Drug Administration (US FDA) had conducted ...

Read more

30 Jun 2025 12:58

News

Marksans Pharma's UK arm gets marketing nod for Oxybutynin Oral solution from UKMHRA

Oxybutynin is used in the treatment of overactive bladder (OAB) symptoms. OAB is a collect...

Read more

19 Jun 2025 10:04

News

Relonchem receives marketing authorization for Metformin Hydrochloride 500mg/ 5 ml Oral Solution in UK

Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketin...

Read more

30 May 2025 09:13

News

Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK

Metformin Hydrochloride is a widely prescribed medication used for the management of type-...

Read more

30 May 2025 09:33

SWOT Analysis Of Marksans Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Marksans Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kopran Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Kopran Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, Kopran Ltd or Marksans Pharma Ltd?

Market cap of Kopran Ltd is 866 Cr while Market cap of Marksans Pharma Ltd is 11,838 Cr

What are the key factors driving the stock performance of Kopran Ltd and Marksans Pharma Ltd?

The stock performance of Kopran Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Kopran Ltd and Marksans Pharma Ltd?

As of July 16, 2025, the Kopran Ltd stock price is INR ₹179.4. On the other hand, Marksans Pharma Ltd stock price is INR ₹261.25.

How do dividend payouts of Kopran Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of Kopran Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions